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Editorials
TB/HIV: An Orphan Disease?
Tuberculosis (TB) and human immunodeficiency virus (HIV)
are tightly interwoven in a catastrophic, global syndemic.
Worldwide, nearly 1.3 million patients with HIV develop TB
each year, and 21% of the estimated 1.8 million HIV-associated
deaths in 2009 were attributed to TB (1). Conversely, HIV has
been responsible for a global resurgence of TB over the past
two decades. It remains the single most important individual-
level risk factor for progression from latent TB infection to
active disease, and has greatly complicated programmatic
control of TB—especially in resource-limited settings. In south-
ern Africa, approximately 70% of newly diagnosed TB cases are
co-infected with HIV. As a result, a recurrent theme in global
public health research is the need to integrate TB and HIV
research and health services (1). Despite the alarming incidence
and severity of TB/HIV co-infection, it remains underfunded,
understudied, and underrepresented at international research
conferences.
This past year, at the 2010 Conference on Retroviruses and
Opportunistic Infections, just 22 (2.2%) of the total 1,022
abstracts addressed TB/HIV co-infection (2). Only a single oral
abstract session included TB/HIV presentations, and even this
was a combined session including other opportunistic infections
and metabolic complications of HIV. By contrast, 76 abstracts
addressed Hepatitis C Virus—another important co-infection,
but one that is responsible for a far lower global burden of
disease and mortality than TB in HIV-infected individuals. This
scarcity of TB/HIV research is, unfortunately, common at
international Pulmonary and Infectious Diseases conferences.
Only 8/1,435 (0.6%) and 37/5,500 (0.7%) posters, presentations,
or symposia at the 2010 Infectious Diseases Society of America
(IDSA) conference (3) and the 2010 American Thoracic Society
conference (4), respectively, focused on TB/HIV co-infection.
Although this may represent a low number of submissions,
acceptances, or both, it is concerning, given the magnitude of
the TB/HIV epidemic. While the International Union Against
Tuberculosis and Lung Disease devotes a larger proportion of
its annual conference program to TB/HIV co-infection, it has,
to date, been primarily focused on programmatic and opera-
tional, rather than laboratory or translational, research (5). This
under-representation of research on TB/HIV co-infection—
reminiscent more of an orphan disease rather than one of the
worst public health catastrophes of our time—may be due to the
historic separation of TB and HIV research and care, under-
funding of TB/HIV research, and the absence of a global market
for TB drugs.
The separation of TB/HIV research between the medical
specialties of infectious diseases and pulmonary medicine has
historical roots. Pulmonary Medicine developed as a specialty
in the pre-antibiotic era as a direct result of chest clinicians’
experience in treating TB. Many of the important insights into
pulmonary physiology and pathophysiology were the result of
early studies in TB. Indeed, the American Thoracic Society was
initially established in 1905 as the American Sanatorium
Association (6). Early investigators of infectious diseases were
not active in TB, for it had already become the domain of
pulmonary specialists, microbiologists, and public health doc-
tors. These divisions have blurred somewhat over time, but
while basic and translational research of HIV infection has been
a focus of leaders in infectious diseases for almost three
decades, there has been much less research focusing specifically
on TB/HIV co-infection. To date, neither the field of infectious
diseases nor that of pulmonary medicine has taken responsi-
bility for promoting research on TB/HIV.
Historical divisions are only part of the problem. TB re-
search remains underfunded by the National Institutes of
Health (NIH) and private sector, relative to the global burden
of disease. In 2009, the NIH spent $169 million on TB research—a
19% increase compared with 2008, but a 10% decrease since
2007 (7). In contrast, the NIH has consistently spent approxi-
mately $2.9 billion per year on HIV/AIDS since 2005. No
matter how urgent the public health needs may be, therefore,
researchers must follow available funding streams. Similarly,
the absence of a Western market for successful TB therapeutics
likely explains why the pharmaceutical and biotechnology
industries have been embarrassingly slow to develop new drugs
and diagnostics.
The lack of integration of TB and HIV research at scientific
meetings has parallels in the programmatic management of both
diseases. In the past several years, there have been increasingly
urgent calls to integrate TB and HIV services, which have
historically existed in isolation (8, 9). Despite the clinical and
economic logic of such integration, however, implementation
has been disappointingly limited. There are valid concerns
about broad integration of HIV and TB services—notably,
infection control in healthcare settings and combined medica-
tion toxicity—but these are manageable issues when properly
anticipated (10). Although some progress in integration has
been made, serious deficits remain. In 2008, provision of co-
trimoxazole preventive therapy and antiretroviral therapy
reached only one third of the levels targeted by the Global
Plan for patients with TB/HIV co-infection (11). Implementa-
tion of the WHO ‘‘Three ‘I’s’’’ agenda (intensified case finding,
isoniazid prophylaxis, and infection control) has also been far
behind global targets (1).
Yet, there is evidence that the tide may at last be changing.
Two key points appear to have seized the attention of the
scientific community: (1) numerous antiretroviral treatment
(ART) cohort studies showing high mortality rates in the first
year after ART initiation—much of it attributable to TB (12);
and (2) reports demonstrating dramatic and early mortality
associated with drug-resistant TB in HIV-infected individuals
(13). Each of these has been a stark reminder that TB control
is essential to improving health in countries with high HIV-
prevalence—even where access to ART is widespread. In re-
sponse, the National Institute of Allergy and Infectious Diseases
(NIAID) recently directed their HIV clinical trials networks to
prioritize TB research (14). NIAID has also developed a task
force to coordinate TB research across its divisions and has
made new money available for this effort.
Innovative strategies by groups such as the TB Alliance and
the Foundation for Innovative New Diagnostics (FIND) have
sought to incentivize the creation of new therapeutic agents and
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TB diagnostics. Areas of important recent investigation include
near-patient, rapid diagnostic tests, novel genotypic analysis of
M. tuberculosis, vaccine development, and the clinical testing of
long-awaited new drugs. Although total NIH funding for TB did
not increase in 2009 relative to 2007, several donors from the
public and private sector (e.g., UK MRC, USAID, European
Commission) increased their TB funding considerably. Still,
total TB funding remains less than a third of projected needs,
according to the Stop TB Partnership (7). Finally, the IDSA’s
Center for Global Health Policy has issued a brief to raise
congressional awareness of the threat posed by ‘‘The Deadly
Duo’’ (15).
Although these are all encouraging signs, much still needs
to be done and it is critical that the momentum be maintained.
As junior pulmonary and infectious diseases TB/HIV re-
searchers, we call on our respective professional societies to
follow through on the initiatives listed above and to promote an
increased visibility of TB/HIV and TB research. Reasonable
first steps might include a call for TB/HIV abstracts, creation of
TB/HIV symposia within conference programs, and concerted
advocacy for increased research funding from the public and
private sectors. The scientific community should approach
integration in the broadest sense—not just at the clinical and
programmatic level, but also in clinical, translational, and bench
research. The recent publication of both a Clinical Infectious
Diseases supplement dedicated to TB and HIV (16) and a review
of HIV-associated TB in The Lancet (17) is, hopefully, an
indicator that these diseases will soon be routinely considered,
treated, and studied together.
Over the past 30 years, research has produced deep un-
derstanding of HIV pathogenesis and more than 25 different
medications, transforming the disease from a universal death
sentence to a chronic, manageable infection. It is time that
TB/HIV co-infection—still claiming so many lives worldwide
and undermining the great strides of antiretroviral therapy—
receives the due attention of our colleagues in the fields of
infectious diseases and pulmonary medicine.
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